Special Issue

Bioactive Natural Products for Novel Drugs

Message from the Guest Editor

Secondary metabolites from medicinal plants or marine organisms are key sources for drug discovery processes and Phyto-based dietary supplements. The importance of natural product isolation, characterization, standardization, and exploring their biological properties through in vivo, in vitro, and in silico methods are necessary for human use. The aim of this issue is to study the chemistry of natural products with defined molecular compounds, followed by their bioactivities and toxicological studies. We intend to feature high-quality research, innovative approaches, and substantial knowledge from various research groups working on natural products, food applications, and natural products-based dietary supplements. This Special Issue covers recent research studies in relation to the discovery of Phyto-active secondary metabolites, natural product applications in nutraceuticals/dietary supplements in terms of analytical studies, formulationbased research, and pharmacological applications for human use from academia, research, and industry.

Guest Editor

Dr. Kumar Katragunta

National Center for Natural Product Research (NCNPR), School of Pharmacy, University of Mississippi, University, MS 38677, USA

Deadline for manuscript submissions

closed (30 June 2024)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/176011

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).